Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration | MicrobiomeTrials← Back to trialsNCT02286089
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2015-04-01Est. Completion: 2021-12-31
Enrollment target: 24 participants Locations- West Coast Retina Medical Group, San Francisco, California, United States
- Cincinnati Eye Institute, Cincinnati, Ohio, United States
- Mid Atlantic Retina, Philadelphia, Pennsylvania, United States
- Hadassah Medical Center, Jerusalem, Israel
- Rabin Medical Center, Petah Tikva, Israel
- Kaplan Medical Center, Rehovot, Israel
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Other microbiome trials you might be interested in
Macular Degeneration
If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent for…
Seongnam, South KoreaEst. completion Apr 30, 2028
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Primary objective:
• To evaluate the change in aqueous humor vascular endothelial growth factor A (VEGF-A) levels after…
Multiple LocationsEst. completion Aug 15, 2026